Ethyl-EPA Treatment of Prodromal Patients

Phase 2

Completed

• Conditions: Schizophrenia Prodrome
• Interventions: Drug: ethyl-eicosapentaenoic acid

• Registration Number: NCT00634361
• Lead Sponsor: Yale University

Brief Summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-09
• Primary Completion: 2005-08
• Study Completion: 2005-08
• Study First Submitted: 2008-03-06
• Study First Submitted QC: 2008-03-06
• Study First Posted: 2008-03-13
• Status Verified: 2014-05
• Last Update Submitted: 2014-05-21
• Last Update Posted: 2014-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

• meets criteria for schizophrenia prodrome

Exclusion Criteria

• any lifetime antipsychotic treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A	ethyl-eicosapentaenoic acid	-

Primary Outcome Measures

Name	Time	Method
conversion to psychosis	one year